申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0458642A1
公开(公告)日:1991-11-27
The present invention is concerned with compounds of formula (I)
wherein
X is a sulphur atom or oxygen atom or a group -NR¹- or -CR¹R²-, in the alpha- or beta-configuration, where R¹ and R² are hydrogen or straight or branched C₁₋₅ alkyl;
X¹ is a C₁₋₅ straight chain or branched alkylene group, a C₃₋₅ straight chain or branched alkenylene group or a substituted or unsubstituted C₆ or C₁₀ aromatic group, the optional substituents on the aromatic group being one or more of C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo and trihalomethyl;
X² is a cyano, carboxyl, carboxamide, hydroxymethyl, C₂₋₅ alkoxycarbonyl, or 5-tetrazolyl group;
Z¹ is a group selected from -NH-CH₂-R³ and -N=CO-R³ wherein R³ is a group selected from -CO-Y and -CH(Y¹)Y, Y being a group selected from C₃₋₈ alkyl, C₃₋₈ alkenyl, phenyl-C₁₋₄ alkyl and phenyl (wherein the phenyl group in both cases is optionally substituted by one or more groups independently selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo and trihalomethyl), cycloalkyl of from 4 to 8 carbon atoms and 5- and 6-membered heterocyclic radicals containing at least one oxygen, sulphur, or nitrogen heteroatom and Y¹ being a group selected from hydroxy, hydrogen, C₁₋₄ alkoxy and C₁₋₅ alkanoyloxy;
Z² is hydrogen, C₁₋₁₂ alkyl (straight or branched), C₂₋₁₂ alkenyl or alkynyl, C₆ or C₁₀ aryl or C₆ or C₁₀ aryl-C₁₋₁₂ alkyl wherein the aryl group is optionally substituted by one or more groups independently selected from phenyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo and trihalomethyl) or cycloalkyl of from 3 to 5 carbon atoms;
and salts, esters and other physiologically functional derivatives thereof.
The preparation of these compounds, medicaments containing them and their use as therapeutic agents are also within the scope of the invention.
本发明涉及式 (I) 的化合物
其中
X 是硫原子或氧原子或基团 -NR¹- 或 -CR¹R²-,呈 α- 或 β-构型,其中 R¹ 和 R² 是氢或直链或支链 C₁₋₅烷基;
X¹ 是 C₁₋₅ 直链或支链亚烷基、C₃₋₅ 直链或支链烯基或取代或未取代的 C₆ 或 C₁₀ 芳基、芳香基团上的任选取代基为 C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤代和三卤甲基中的一个或多个;
X² 是氰基、羧基、羧酰胺基、羟甲基、C₂₋₅ 烷氧基羰基或 5-四唑基;
Z¹ 是选自 -NH-CH₂-R³ 和 -N=CO-R³ 的基团,其中 R³ 是选自 -CO-Y 和 -CH(Y¹)Y 的基团,Y 是选自 C₃₋₈ 烷基的基团、C₃₋₈烯基、苯基-C₁₋₄烷基和苯基(其中这两种情况下的苯基可选择被一个或多个独立选自 C₁₋₄ 烷基的基团取代)、C₁₋₄烷氧基、硝基、卤代和三卤甲基)、4 至 8 个碳原子的环烷基以及含有至少一个氧、硫或氮杂环基的 5 和 6 元杂环基中任选取代的一个或多个基团、Y¹ 是选自羟基、氢、C₁₋₄ 烷氧基和 C₁₋₅ 烷酰氧基的基团;
Z² 是氢、C₁₋₁₂烷基(直链或支链)、C₂₋₁₂烯基或炔基、C₆ 或 C₁₀ 芳基或 C₆ 或 C₁₀ 芳基-C₁₋₁₂烷基,其中芳基任选被一个或多个独立选自苯基的基团取代、C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤代和三卤甲基)或 3 至 5 个碳原子的环烷基;
及其盐类、酯类和其他生理功能衍生物。
这些化合物的制备、含有这些化合物的药物及其作为治疗剂的用途也属于本发明的范围。